Wenn Sie das Fenster schließen, wird Ihre Konfiguration nicht gespeichert, es sei denn, Sie haben Ihren Artikel in die Bestellung aufgenommen oder zu Ihren Favoriten hinzugefügt.
Klicken Sie auf OK, um das MILLIPLEX® MAP-Tool zu schließen oder auf Abbrechen, um zu Ihrer Auswahl zurückzukehren.
Wählen Sie konfigurierbare Panels & Premixed-Kits - ODER - Kits für die zelluläre Signaltransduktion & MAPmates™
Konfigurieren Sie Ihre MILLIPLEX® MAP-Kits und lassen sich den Preis anzeigen.
Konfigurierbare Panels & Premixed-Kits
Unser breites Angebot enthält Multiplex-Panels, für die Sie die Analyten auswählen können, die am besten für Ihre Anwendung geeignet sind. Unter einem separaten Register können Sie das Premixed-Cytokin-Format oder ein Singleplex-Kit wählen.
Kits für die zelluläre Signaltransduktion & MAPmates™
Wählen Sie gebrauchsfertige Kits zur Erforschung gesamter Signalwege oder Prozesse. Oder konfigurieren Sie Ihre eigenen Kits mit Singleplex MAPmates™.
Die folgenden MAPmates™ sollten nicht zusammen analysiert werden: -MAPmates™, die einen unterschiedlichen Assaypuffer erfordern. -Phosphospezifische und MAPmate™ Gesamtkombinationen wie Gesamt-GSK3β und Gesamt-GSK3β (Ser 9). -PanTyr und locusspezifische MAPmates™, z.B. Phospho-EGF-Rezeptor und Phospho-STAT1 (Tyr701). -Mehr als 1 Phospho-MAPmate™ für ein einziges Target (Akt, STAT3). -GAPDH und β-Tubulin können nicht mit Kits oder MAPmates™, die panTyr enthalten, analysiert werden.
.
Bestellnummer
Bestellinformationen
St./Pkg.
Liste
Dieser Artikel wurde zu Ihren Favoriten hinzugefügt.
Wählen Sie bitte Spezies, Panelart, Kit oder Probenart
Um Ihr MILLIPLEX® MAP-Kit zu konfigurieren, wählen Sie zunächst eine Spezies, eine Panelart und/oder ein Kit.
Custom Premix Selecting "Custom Premix" option means that all of the beads you have chosen will be premixed in manufacturing before the kit is sent to you.
Catalogue Number
Ordering Description
Qty/Pack
List
Dieser Artikel wurde zu Ihren Favoriten hinzugefügt.
Spezies
Panelart
Gewähltes Kit
Menge
Bestellnummer
Bestellinformationen
St./Pkg.
Listenpreis
96-Well Plate
Menge
Bestellnummer
Bestellinformationen
St./Pkg.
Listenpreis
Weitere Reagenzien hinzufügen (MAPmates erfordern die Verwendung eines Puffer- und Detektionskits)
Menge
Bestellnummer
Bestellinformationen
St./Pkg.
Listenpreis
48-602MAG
Buffer Detection Kit for Magnetic Beads
1 Kit
Platzsparende Option Kunden, die mehrere Kits kaufen, können ihre Multiplex-Assaykomponenten in Kunststoffbeuteln anstelle von Packungen erhalten, um eine kompaktere Lagerung zu ermöglichen.
Dieser Artikel wurde zu Ihren Favoriten hinzugefügt.
Das Produkt wurde in Ihre Bestellung aufgenommen
Sie können nun ein weiteres Kit konfigurieren, ein Premixed-Kit wählen, zur Kasse gehen oder das Bestell-Tool schließen.
Anti-hCG beta 3, clone P3W80, Cat. No. MABS2062, is a mouse monoclonal antibody that detects Choriogonadotropin subunit beta 3 and has been tested for use in ELISA, Flow Cytometry, and Immunohistochemistry (Paraffin).
More>>Anti-hCG beta 3, clone P3W80, Cat. No. MABS2062, is a mouse monoclonal antibody that detects Choriogonadotropin subunit beta 3 and has been tested for use in ELISA, Flow Cytometry, and Immunohistochemistry (Paraffin). Less<<
Choriogonadotropin subunit beta 3 (UniProt: P0DN86; also known as Choriogonadotropin subunit beta, CG-beta, Chorionic gonadotropin chain beta, hCG) is encoded by the CGB3 (also known as CGB, CGB5, CBG8) gene (Gene ID: 1082, 93659, 94115) in human. hCG is a complex glycoprotein composed of two glycosylated subunits alpha and beta that are non-covalently associated. The alpha subunit is shown to be identical to that found in the pituitary gonadotropin hormones (LH, FSH and TSH). However, the beta subunits are distinct in each of the hormones and confer receptor and biological specificity. It displays high expression in placenta throughout pregnancy with peak during the first trimester. hCG beta 3 is synthesized with signal peptide (aa 1-20), which is cleaved off to generate the mature form. hCG plays an essential role in pregnancy and maternal adaptation. It stimulates the ovaries to synthesize the steroids that are essential for the maintenance of pregnancy. Two isoforms of hCG beta 3 have been described that are produced by alternative splicing.
References
Product Information
Format
Purified
Presentation
Purified mouse monoclonal antibody IgG1 in PBS without azide.
Applications
Application
Anti-hCG beta 3, clone P3W80, Cat. No. MABS2062, is a mouse monoclonal antibody that detects Choriogonadotropin subunit beta 3 and has been tested for use in ELISA, Flow Cytometry, and Immunohistochemistry (Paraffin).
Key Applications
ELISA
Flow Cytometry
Immunohistochemistry (Paraffin)
Application Notes
Flow Cytometry Analysis: A representative lot detected hCG beta 3 in Flow Cytometry applications (Arora, G., et.l al. (2016). Ann Nucl Med. 30(5):334-45).
ELISA Analysis: A representative lot detected hCG beta 3 in ELISA applications (Arora, G., et.l al. (2016). Ann Nucl Med. 30(5):334-45).
Biological Information
Immunogen
Purified human chorionic gonadotropin, beta subunit.
Clone
P3W80
Concentration
Please refer to lot specific datasheet.
Host
Mouse
Specificity
Clone P3W80 is a mouse monoclonal antibody that detects human Choriogonadotropin subunit beta 3.
Evaluated by Immunohistochemistry (Paraffin) in human placenta tissue sections.
Immunohistochemistry (Paraffin) Analysis: A 1:250 dilution of this antibody detected hCG beta 3 in human placenta tissue sections.
Usage Statement
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
Storage and Shipping Information
Storage Conditions
Stable for 1 year at -20°C from date of receipt. Handling Recommendations: Upon receipt and prior to removing the cap, centrifuge the vial and gently mix the solution. Aliquot into microcentrifuge tubes and store at -20°C. Avoid repeated freeze/thaw cycles, which may damage IgG and affect product performance.
Evaluation of cytotoxic and tumor targeting capability of (177)Lu-DOTATATE-nanoparticles: a trailblazing strategy in peptide receptor radionuclide therapy. Arora, G; Dubey, P; Shukla, J; Ghosh, S; Bandopadhyaya, G Ann Nucl Med
30
334-45
2015
We propose an innovative strategy of nanoparticle-mediated-peptide receptor radionuclide therapy (PRRT) employing PLGA-nanoparticles together with anti-β-hCG antibodies that can protect kidneys from radiation damage while simultaneously enhancing its tumor targeting and cytotoxic ability for somatostatin receptor (SSR) positive tumors.PEG-coated-(177)Lu-DOTATATE-PLGA-nanoparticles (PEG-LuD-NP) were formulated and characterized. In vitro toxicity of these particles was tested on human glioblastoma cell line U87MG over a radiation dose range of 19-78 Gy, using MTT assay and flow cytometry. To further enhance cytotoxicity and test the feasibility of active tumor targeting, apoptosis-inducing anti-β-hCG monoclonal antibodies were employed in vitro, after confirming expression of β-hCG on U87MG. In vivo tumor targeting ability of these particles, in comparison to uncoated particles and un-encapsulated (177)Lu-DOTATATE, was assessed by intravenous administration in tumor-induced wistar rats. Rats were first imaged in a gamma camera followed by euthanasia for organ extraction and counting in gamma counter.The particles were spherical in shape with mean diameter of 300 nm. Highest cytotoxicity that could be achieved with PEG-LuD-NP, on radio-resistant U87MG cells, was 35.8 % due to complex cellular response triggered by ionizing radiation. Interestingly, synergistic action of antibodies and PEG-LuD-NP doubled the cytotoxicity (80 %). PEG-LuD-NP showed the highest tumor uptake (4.3 ± 0.46 % ID/g) as compared to (177)Lu-DOTATATE (3.5 ± 0.31 %) and uncoated-(177)Lu-DOTATATE-nanoparticles (3.4 ± 0.35 %) in tumor-inoculated wistar rats (p < 0.001). Renal uptake/retention was decreased 3-4 folds with these particles, resulting in the highest tumor-to-kidney ratio (8.58; p < 0.01) while tumor-to-liver and tumor-to-bone ratios were comparable to un-encapsulated-drug.Nanocarrier-mediated-PRRT is an effective way of targeting SSR positive tumors for enhanced cytoxicity and reduced renal radiation dose associated with conventional PRRT. To our knowledge of literature, this is the first study to establish in vitro and in vivo efficacy profile of nanoparticles in PRRT providing a stepping-stone for undergoing and future research endeavors in the direction of abating associated radiation concerns of radionuclide therapy and may offer a paradigm shift in PRRT strategy.
